Benzodiazepine Use in Perinatal Anxiety: Safety, Risks, and Alternatives

The Clinical Context

Anxiety disorders are the most common perinatal psychiatric conditions, affecting an estimated 15 to 20 percent of pregnant and postpartum people. Benzodiazepines are one of the most frequently prescribed psychotropic medication classes overall, and patients with pre-existing anxiety prescriptions will frequently continue or request them during pregnancy.

Managing benzodiazepine prescribing in perinatal patients requires navigating a historical literature that overstated teratogenic risk, a legitimate set of clinical concerns in late pregnancy and breastfeeding, and the reality that untreated severe anxiety carries its own fetal and obstetric consequences.

---

Teratogenicity: What the Evidence Actually Shows

The oral cleft concern

The initial concerns about benzodiazepine teratogenicity centered on a possible association with oral cleft malformations (cleft lip/palate). This association was based on early case-control studies and case reports in the 1970s and 1980s. Subsequent meta-analyses of better-controlled data found either no significant association or a very small one (absolute risk increase from approximately 0.06 to 0.11 percent -- a doubling of a very low baseline risk).

Current consensus: benzodiazepine exposure in the first trimester does not carry a clinically meaningful teratogenic risk for oral clefts. The historical concern should not drive clinical decisions, though it is worth discussing with patients who ask.

Overall malformation risk

Multiple large registry and cohort studies have not identified a pattern of congenital malformations attributable to benzodiazepine exposure. This finding is consistent across studies adequately controlling for maternal psychiatric illness.

---

Late Pregnancy and Neonatal Concerns

This is where the more substantiated concerns exist.

Neonatal withdrawal syndrome: Maternal benzodiazepine use in the third trimester, particularly at higher doses or with long-half-life agents, can produce neonatal withdrawal: irritability, tremor, hypertonia, poor feeding, and in more severe cases, respiratory depression and hyperthermia. Neonatal benzodiazepine withdrawal is generally manageable but can require neonatal unit observation.

Floppy infant syndrome: High-dose benzodiazepine use at term is associated with neonatal hypotonia, hypothermia, and respiratory depression at delivery. This is largely a dose- and timing-dependent concern and is most relevant with scheduled high-dose use close to delivery.

Clinical implications:

• Avoid high-dose, long-acting benzodiazepine use in the third trimester when possible
• If a patient is on chronic benzodiazepines through pregnancy, the obstetric team should be aware for neonatal monitoring
• Short-term low-dose use for acute anxiety is a different risk profile than chronic scheduled use

---

Use in Breastfeeding

Benzodiazepines transfer into breast milk at varying levels. Key points:

Agent selection matters. Long-acting agents (diazepam, chlordiazepoxide) accumulate in infant serum more than short-acting agents. Lorazepam is the preferred agent in breastfeeding patients due to no active metabolites and relatively lower milk transfer.

Relative infant doses: Lorazepam RID approximately 2 to 3 percent; diazepam RID 6 to 8 percent (higher with chronic use due to active metabolite accumulation).

Clinical approach:

• If benzodiazepine use is necessary in a breastfeeding patient, use lorazepam at the lowest effective dose
• Single bedtime dosing minimizes infant exposure during waking feeding times
• Avoid chronic scheduled use; taper to as-needed when possible
• Consult LactMed for current data on individual agents

Infant monitoring: Sedation, poor feeding, or reduced weight gain in a breastfed infant whose mother is on a benzodiazepine warrants review and possible dose reduction.

---

Clinical Positioning: When Benzodiazepines Are Appropriate

Acute anxiety management during medication titration. The most defensible use: a patient starting an SSRI or SNRI who needs bridging support during the 2 to 4 weeks before the antidepressant reaches therapeutic effect. Short course, specific endpoint, clear taper plan.

Panic disorder with acute attacks. Benzodiazepines provide reliable rapid relief for panic attacks. For patients with panic disorder, an as-needed benzodiazepine alongside ongoing SSRI treatment is a standard approach.

Acute situational anxiety. Procedures, medical appointments, anticipated high-anxiety situations -- as-needed use for specific events rather than scheduled daily dosing.

Not appropriate as maintenance treatment for anxiety. Benzodiazepines do not address the underlying anxiety disorder and carry risk of tolerance, dependence, and discontinuation syndrome. SSRIs and SNRIs are the appropriate maintenance treatment for anxiety disorders in perinatal patients, with or without benzodiazepine bridging.

---

Evidence-Based Alternatives

For most perinatal anxiety presentations, benzodiazepines should be the adjunctive option, not the primary treatment.

SSRIs and SNRIs: First-line maintenance pharmacotherapy for perinatal anxiety disorders. See the companion article on antidepressants during pregnancy for safety profiles.

Cognitive behavioral therapy: Strong evidence base for perinatal anxiety. CBT targeting worry, avoidance, and catastrophic cognition is effective without pharmacological risk. A perinatal mental health therapist who offers CBT or exposure-based therapy is the most targeted referral.

Buspirone: Non-benzodiazepine anxiolytic with limited perinatal safety data. Some data suggests acceptable pregnancy profile; LactMed indicates low milk transfer. Slow onset (2 to 4 weeks) limits utility for acute anxiety. May be appropriate as an adjunct in patients who cannot tolerate or do not want benzodiazepines for bridging.

Beta-blockers (propranolol, atenolol): For situational anxiety with prominent physical symptoms (heart racing, tremor), low-dose propranolol is sometimes used on an as-needed basis. Generally compatible with pregnancy at low doses; avoid in patients with reactive airway disease.

Hydroxyzine: Antihistamine with anxiolytic properties. Short-acting, as-needed use. Limited data in pregnancy but long clinical use record. Sedating; suitable for acute situational anxiety or bedtime use for anxiety-related insomnia.

---

Managing Patients Already on Benzodiazepines

A patient who presents in early pregnancy already on a benzodiazepine presents a specific clinical challenge.

Abrupt discontinuation is not appropriate. Benzodiazepine withdrawal can cause seizures and is dangerous in pregnancy.

Taper if possible and clinically appropriate. If the patient has mild-to-moderate anxiety that is currently managed by a chronic low-dose benzodiazepine, a gradual taper with concurrent initiation of an SSRI and/or therapy may achieve discontinuation without clinical decompensation.

Continue at the lowest effective dose if taper is not feasible. For patients with severe anxiety where taper is not clinically safe, continue the current regimen with the obstetric team informed, switch to a shorter-acting agent when possible, and plan for neonatal monitoring.

Do not let concern about the medication drive abrupt discontinuation that creates clinical risk. The outcome of untreated severe anxiety or withdrawal in pregnancy is not safer than managed benzodiazepine continuation.

---